| Literature DB >> 28955396 |
Won-Woo Seo1, Sung Eun Kim1, Myung-Soo Park1, Jun-Hee Lee1, Dae-Gyun Park1, Kyoo-Rok Han1, Dong-Jin Oh1.
Abstract
BACKGROUND AND OBJECTIVES: Trapped thrombus in patent foramen ovale (PFO) is a rare complication of pulmonary embolism that may lead to tragic clinical events. The aim of this study was to identify the optimal treatment for different clinical situations in patients with trapped thrombus in a PFO by conducting a literature review. SUBJECTS AND METHODS: A PubMed database search was conducted from 1991 through 2015, and 194 patients (185 articles) with trapped thrombus in a PFO were identified. Patient characteristics, paradoxical embolic events, and factors affecting 60-day mortality were analyzed retrospectively.Entities:
Keywords: Foramen ovale, patent; Pulmonary embolism; Review, systematic
Year: 2017 PMID: 28955396 PMCID: PMC5614954 DOI: 10.4070/kcj.2016.0295
Source DB: PubMed Journal: Korean Circ J ISSN: 1738-5520 Impact factor: 3.243
Figure 1Echocardiographic images of trapped thrombi in the PFO. (A) Initial transthoracic echocardiography shows a large hypermobile mass that was consistent with a thrombus trapped in a PFO. (B) Transesophageal echocardiography obtained 1 day after thrombolysis with intravenous alteplase shows a small remnant thrombus trapped in the PFO. (C) Repeat transesophageal echocardiography obtained after 1-month of oral anticoagulation therapy confirmed complete resolution of the thrombus trapped in the PFO, and (D) agitated saline test shows a positive result for the PFO.
PFO = patent foramen ovale.
Baseline characteristics of patients with trapped thrombus in PFO
| Characteristics | Overall population (n=194) | Treatment option | ||||
|---|---|---|---|---|---|---|
| Surgery (n=112, 57.7%) | Thrombolysis (n=28, 14.4%) | Anticoagulation (n=54, 27.8%) | p value | |||
| Age | 59.3±16.4 | 56.5±15.7 | 57.8±16.0 | 66.1±16.4 | 0.002* | |
| Men | 100 (51.5) | 57 (50.9) | 12 (42.9) | 31 (57.4) | 0.447 | |
| Cause of pulmonary embolism | - | - | - | - | 0.848 | |
| Unprovoked | 129 (66.5) | 73 (65.2) | 20 (71.4) | 36 (66.7) | - | |
| Provoked | 51 (26.3) | 29 (25.9) | 7 (25.0) | 15 (27.8) | - | |
| Cancer related | 14 (7.2) | 10 (8.9) | 1 (3.6) | 3 (5.6) | - | |
| Initial shock or arrest | 40 (20.6) | 18 (16.1) | 14 (50.0) | 8 (14.8) | <0.001† | |
| Pre-treatment embolism | 73 (37.6) | 36 (32.2) | 10 (35.7) | 27 (50.0) | 0.134 | |
| Stroke (including TIA) | 48 (24.7) | 19 (17.0) | 6 (21.4) | 23 (42.6) | - | |
| Non-stroke embolism | 25 (12.9) | 17 (15.2) | 4 (14.3) | 4 (7.4) | - | |
| IVC filter | 39 (20.1) | 32 (28.6) | 3 (10.7) | 4 (7.4) | 0.003‡ | |
| Publication year | - | - | - | - | 0.483 | |
| ≤2005 | 84 (43.3) | 50 (44.6) | 14 (50.0) | 20 (37.0) | - | |
| >2005 | 110 (56.7) | 62 (55.4) | 14 (50.0) | 34 (63.0) | - | |
Values are presented as mean±standard deviation or number (%).
IVC = inferior vena cava; PFO = patent foramen ovale; TIA = transient ischemic attack.
*Post-hoc analysis: surgery vs. anticoagulation, p<0.010; †Post-hoc analysis: thrombolysis vs. surgery, p<0.010; thrombolysis vs. anticoagulation, p<0.010; ‡Post-hoc analysis: surgery vs. anticoagulation, p<0.010.
Diagnostic accuracy of echocardiography for trapped thrombus in PFO and follow-up echocardiography result
| Initial diagnostic tool | Performed in patients (n=194) | Diagnostic accuracy | |
|---|---|---|---|
| Transthoracic echocardiography | 166 (85.5%) | 145 (87.3%) | |
| Transesophageal echocardiography | 176 (90.7%) | 176 (100%) | |
| Follow-up performed patients | 12 (42.9%) | 34 (63.0%) | |
| Time to mean follow-up, day | 3.0±2.7 | 12.9±9.6 | |
| Complete resolution of thrombus | 8 (66.7%) | 23 (67.6%) | |
Presenting symptoms or signs, cause of pulmonary embolism, and sites of pre-embolization in patients with trapped thrombus in PFO
| Symptom or sign | No. (%) of patients (n=194) | |
|---|---|---|
| Dyspnea | 154 (79.4%) | |
| Chest pain | 64 (33.0%) | |
| Lower extremity edema | 28 (14.4%) | |
| Syncope | 34 (17.5%) | |
| Focal neurological deficit | 32 (16.5%) | |
| Peripheral arterial occlusion | 17 (8.8%) | |
| Cardiac arrest | 6 (3.1%) | |
| Unprovoked | ||
| Unknown first embolism | 109 (56.2%) | |
| Recurred thromboembolism | 8 (4.1%) | |
| Antiphospholipid syndrome | 4 (2.1%) | |
| Inherited thrombophilia | 8 (4.1%) | |
| Provoked | ||
| Prolonged hospitalization | 19 (9.8%) | |
| Post-operative | 22 (11.3%) | |
| Major trauma | 3 (1.5%) | |
| Venous external compression | 4 (2.1%) | |
| Pregnancy | 2 (1.0%) | |
| Economy class syndrome | 1 (0.5%) | |
| Cancer related | 14 (7.2%) | |
| Brain (Stroke or TIA) | 48 (24.7%) | |
| Peripheral artery | 15 (7.7%) | |
| Visceral organ | 7 (3.6%) | |
| Coronary artery | 6 (3.1%) | |
PFO = patent foramen ovale; TIA = transient ischemic attack.
Treatment result according to treatment options
| Characteristics | Overall population (n=194) | Treatment option | ||||
|---|---|---|---|---|---|---|
| Surgery (n=112, 57.7%) | Thrombolysis (n=28, 14.4%) | Anticoagulation (n=54, 27.8%) | p value | |||
| Post-treatment embolism | 16 (8.3) | 5 (4.5) | 4 (14.3) | 7 (13.0) | 0.044 | |
| Stroke (including TIA) | 11 (5.7) | 4 (3.6) | 2 (7.1) | 5 (9.3) | - | |
| Non-stroke embolism | 5 (2.6) | 1 (0.9) | 2 (7.1) | 2 (3.7) | - | |
| Total deaths | 27 (13.9) | 7 (6.3) | 10 (35.7) | 10 (18.5) | <0.001 | |
| Cardiogenic shock | 18 (9.3) | 4 (3.6) | 7 (25.0) | 7 (13.0) | - | |
| Stroke | 5 (2.6) | 1 (0.9) | 2 (7.1) | 2 (3.7) | - | |
| Bleeding | 2 (1.0) | - | 1 (3.6) | 1 (1.9) | - | |
| Post-surgery ARDS | 2 (1.0) | 2 (1.8) | - | - | - | |
Values are presented as number (%).
ARDS = acute respiratory distress syndrome; TIA = transient ischemic attack.
Figure 2Mortality rate according to treatment options published from 1991 through 2015.
Figure 3Treatment-related mortality rate according to publication year (A) from 1991 to 2005, and (B) from 2006 to 2015.
Multivariable Cox regression analysis for 60-day mortality
| Variables | HR | CI | p value | ||
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Aged ≥60 years | 2.04 | 0.84 | 4.97 | 0.117 | |
| Men | 0.58 | 0.25 | 1.37 | 0.220 | |
| Initial shock or arrest | 4.90 | 1.99 | 12.01 | 0.001 | |
| Pre-embolization | 1.45 | 0.66 | 3.21 | 0.360 | |
| Cause of pulmonary embolism | - | - | - | - | |
| Unprovoked | 1.00 | - | - | - | |
| Provoked | 1.13 | 0.49 | 2.62 | 0.770 | |
| Cancer related | 1.32 | 0.59 | 2.93 | 0.490 | |
| IVC filter | 0.39 | 0.09 | 1.71 | 0.210 | |
| Treatment option (overall) | - | - | - | - | |
| Surgery | 1.00 | - | - | - | |
| Thrombolysis | 3.40 | 1.21 | 9.61 | 0.021 | |
| Anticoagulation | 1.99 | 0.70 | 5.69 | 0.190 | |
| Treatment option (publication year ≤2005)* | |||||
| Surgery | 1.00 | - | - | - | |
| Thrombolysis | 1.39 | 0.38 | 5.04 | 0.618 | |
| Anticoagulation | 1.03 | 0.28 | 3.78 | 0.960 | |
| Treatment option in overall (publication year >2005)* | |||||
| Surgery | 1.00 | - | - | - | |
| Thrombolysis | 22.99 | 2.26 | 233.93 | 0.008 | |
| Anticoagulation | 5.60 | 0.59 | 53.27 | 0.134 | |
CI = confidence interval; HR = hazard ratio; IVC = inferior vena cava.
*Result of the multivariate analysis after adjustment for age, sex, pre-embolization, cause of pulmonary embolism, and IVC filter replacement.
Figure 4Mortality rate according to treatment options, with or without cardiogenic shock.
HR = hazard ratio; IVC = inferior vena cava.
*Shock means initially presented with cardiogenic shock or cardiac arrest, †Result of the multivariate analysis after adjustment for age, sex, pre-embolization, cause of pulmonary embolism, and IVC filter replacement.